Thus, these findings establish IGF2BP2 as markedly upregulated in thyroid carcinoma, with highest expression in aggressive subtypes, and significantly associated with poor clinical outcomes. This evidence concerns the gene IGF2BP2 and thyroid gland carcinoma.